Treatment

https://apps.who.int/iris/bitstream/handle/10665/352904/9789240047754-eng.pdf

WHO treatment guidelines for drug-resistant TB treatment

WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update

Refer to Annex 10: Summaries of unpublished data and analysis plans used for the recommendations in the WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update.

https://iris.who.int/bitstream/handle/10665/311390/WHO-CDS-TB-2019.3-eng.pdf

5.1 Drug-susceptible TB

5.1.1 Guidelines update 2010 to 2022

Refer to WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment: web annexes. Web Annex 4

https://iris.who.int/handle/10665/353398

4.1. Drug-susceptible TB

Research questions in a Population, Intervention, Comparator, Outcomes (PICO) format are listed below as they related to the recommendations retained in this policy consolidation.

4.1.1. Guideline update 2010

Recommendation 1. PICO question

Should new pulmonary TB patients be treated with the 6-month or the 2-month rifampicin regimen?

Recommendation 2. PICO question

WHO guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update

Funding for the meetings and reviews involved in the updating of the guidelines came entirely from the United States Agency for International Development (USAID). The experts on the Guideline Development Group (GDG) and the institutions where they work contributed time for the various discussions and other activities involved in the update process.

2009 Guideline Development Group:

All members of the group completed a Declaration for the Conflict of Interest; there were no conflicts declared.

2016 Guideline Development Group:

The following members declared no interests: Si Thu Aung; Frank Bonsu; Jeremiah Chakaya; Lucy Chesire; Daniela Cirillo; Poonam Dhavan; Kathy Fiekert; Andrei Mariandyshev; Nguyen Viet Nhung; Ejaz Qadeer; Abdul Hamid Salim; Holger Schünemann; Pedro Suarez; Justin Wong Yun Yaw.

Drug-susceptible TB treatment

Participants in the Guideline Development group meeting on Drug-susceptible TB in 2009

Guideline Development Group

Solange Cavalcante, TB Control Program Coordinator, Rio de Janeiro municipality, Rio de Janeiro, RJ, Brazil

Jeremiah Muhwa Chakaya (Chairperson), Technical Expert, National Leprosy and TB Programme, Kenya Medical Research Institute, Nairobi, Kenya 

Since 2007, the guideline development process within the WHO has been overseen by the WHO Guidelines Review Committee (GRC), which follows internationally recognized standards such as the GRADE approach [Grading of Recommendations Assessment, Development, and Evaluation], to support a structured and transparent methodology for policy-making. The policy recommendations presented in the guideline document were developed following the standards and updated procedures as described in the WHO Handbook for Guideline Development.